ライフサイエンスコーパス: isocitrate dehydrogenase

1 ive carboxylation flux through mitochondrial isocitrate dehydrogenase.

2 mes, notably the mitochondrial NAD-dependent isocitrate dehydrogenase.

3 inated hydroxyl group of isocitrate bound to isocitrate dehydrogenase.

4 catalytic activity of porcine NADP-dependent isocitrate dehydrogenase.

5 d crystal structure of porcine NADP-specific isocitrate dehydrogenase.

6 the tetragonal and the orthorhombic forms of isocitrate dehydrogenase.

7 n, and purified to yield homogeneous porcine isocitrate dehydrogenase.

8 isiae Idp3p, a peroxisomal NADP(+)-dependent isocitrate dehydrogenase.

9 most extensively studied among the mammalian isocitrate dehydrogenases.

10 Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequ

11 tive carboxylation of alpha-ketoglutarate by isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) was recen

12 Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the

13 1 was exclusive to tumors carrying wild-type isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and was

14 Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been ide

15 sue of Blood, Shi et al describe the role of isocitrate dehydrogenase 1 (idh1) and idh2 in developmen

16 Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in cancer st

17 Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydro

18 Monoallelic point mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) and its mitochondrial

19 Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature o

20 Mutations of isocitrate dehydrogenase 1 (IDH1) are frequently found i

21 Gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) are key drivers of hem

22 Here, we characterize isocitrate dehydrogenase 1 (IDH1) as a transcriptional t

23 in HuR-deficient PDAC cell lines identified isocitrate dehydrogenase 1 (IDH1) as the sole antioxidan

24 Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)

25 Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently

26 Mutant isocitrate dehydrogenase 1 (IDH1) catalyzes the producti

27 Isocitrate dehydrogenase 1 (IDH1) catalyzes the reversib

28 Gain-of-function mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

29 Mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the mos

30 The recent identification of isocitrate dehydrogenase 1 (IDH1) gene mutations in glio

31 Hotspot mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in a number

32 Two mutant forms (R132H and R132C) of isocitrate dehydrogenase 1 (IDH1) have been associated w

33 nd recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients

34 Isocitrate dehydrogenase 1 (IDH1) is mutated in various

35 Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as t

36 anscripts were found in GBMs irrespective of isocitrate dehydrogenase 1 (IDH1) mutation status.

37 Absence of isocitrate dehydrogenase 1 (IDH1) mutation, asymptomatic

38 Isocitrate dehydrogenase 1 (IDH1) mutations occur in mos

39 Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gl

40 exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2.

41 dromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of whi

42 Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial h

43 The human, cytosolic enzyme isocitrate dehydrogenase 1 (IDH1) reversibly converts is

44 Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by

45 Mutation at the R132 residue of isocitrate dehydrogenase 1 (IDH1), frequently found in g

46 One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in m

47 that can modulate the activity of the enzyme isocitrate dehydrogenase 1 (IDH1).

48 se reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1).

49 Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key

50 Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer

51 zygously expressed single-point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2, respect

52 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been disc

53 Mutations in the genes encoding isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in a var

54 Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in sever

55 aking is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are

56 Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present i

57 Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the development

58 ers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-kappaB pathway, an

59 IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of

60 Isocitrate dehydrogenase 1 mutations drive human gliomag

61 rganization 2007 tumor grade, histology, and isocitrate dehydrogenase 1 R132H mutational status.

62 ade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor sam

63 orme that identified IDH1, the gene encoding isocitrate dehydrogenase 1, as target for cancer-driving

64 With DESI MS, we identify isocitrate dehydrogenase 1-mutant tumors with both high

65 e (R-2HG), produced at high levels by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was repor

66 Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG islan

67 d hematopoietic differentiation in AML after isocitrate dehydrogenase 1/2 mutation and 2-hydroxygluta

68 levels in cancer cells with gain-of-function isocitrate dehydrogenase 1/2 mutations.

69 g genetic anchor to drive patient selection (isocitrate dehydrogenase 1/2, Enolase 2).

70 Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have b

71 Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur

72 omatic point mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).

73 n the tricarboxylic acid (TCA) cycle enzymes isocitrate dehydrogenases 1 and 2 (IDH1/2) highlights th

74 tions in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several

75 Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that produce

76 Recently, it was shown that somatic isocitrate dehydrogenase-1 (IDH1) mutations, frequently

77 metabolism was highly dependent on cytosolic isocitrate dehydrogenase-1 (IDH1), because the activity

78 This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is a

79 Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common driver

80 hmdC levels were independent of mutations in isocitrate dehydrogenase-1.

81 The development of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mu

82 pecies (ROS) by deacetylating and activating isocitrate dehydrogenase 2 (IDH2) and superoxide dismuta

83 We show that downregulation of isocitrate dehydrogenase 2 (IDH2) and TET family enzymes

84 Mitochondrial isocitrate dehydrogenase 2 (IDH2) converts NADP(+) to NA

85 The mitochondrial matrix protein isocitrate dehydrogenase 2 (IDH2) is a major source of N

86 ochondrial superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) observed in untreated

87 Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in approximately

88 Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers,

89 ons in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2

90 and colleagues demonstrate the mutations in isocitrate dehydrogenase 2 (IDH2), commonly found in acu

91 tly deacetylates and activates mitochondrial isocitrate dehydrogenase 2 (Idh2), leading to increased

92 antioxidant system through the regulation of isocitrate dehydrogenase 2 (Idh2).

93 of unfavorable outcome, such as mutations in isocitrate dehydrogenase 2 (IDH2-R172) and overexpressio

94 rate-limiting tricarboxylic acid cycle (TCA) isocitrate dehydrogenase 2 and superoxide dismutase 2, c

95 findings demonstrate that MitEpac1 inhibits isocitrate dehydrogenase 2 via the mitochondrial recruit

96 which in turn decreased expression of IDH2 (isocitrate dehydrogenase 2).

97 pment of acquired isocitrate dehydrogenase-1/isocitrate dehydrogenase-2 mutations has been described

98 ticipation of concurrent NADPH sources (i.e. isocitrate dehydrogenase-2, malic enzymes, and glutamate

99 f the pyruvate dehydrogenase complex (-41%), isocitrate dehydrogenase (-27%), and the alpha-ketogluta

100 nd that the aberrant expression of wild-type isocitrate dehydrogenase 3alpha (IDH3alpha), a subunit o

101 tion cryo-EM structures of the cancer target isocitrate dehydrogenase (93 kDa) and identify the natur

102 termediates reveals the reversibility of the isocitrate dehydrogenase + aconitase reactions, even in

103 rogenase, 2-oxoxglutarate dehydrogenase, and isocitrate dehydrogenase activities of the Krebs cycle i

104 The mutant was devoid of isocitrate dehydrogenase activity and of immunologically

105 The maximum level of isocitrate dehydrogenase activity during anaerobic growt

106 hypoxia elicited both aconitase and NADP(+)-isocitrate dehydrogenase activity losses.

107 Hepatic isocitrate dehydrogenase activity was also decreased, wh

108 of Bradyrhizobium japonicum USDA110 lacking isocitrate dehydrogenase activity was created to determi

109 ining aconitase 12-fold but had no effect on isocitrate dehydrogenase activity, which was assayed as

110 regulates activity of the TCA cycle enzymes isocitrate dehydrogenase and alpha-ketoglutarate dehydro

111 inase, pyruvate kinase, phosphofructokinase, isocitrate dehydrogenase and citric synthase) tend to be

112 ssion changes of some metabolic genes (e.g., isocitrate dehydrogenase and fumarate hydratase) may enh

113 compartmentalized isozymes of NADP+-specific isocitrate dehydrogenase and in the gene encoding glucos

114 ocitrate dehydrogenase, cocrystallization of isocitrate dehydrogenase and isocitrate dehydrogenase ki

115 so investigated inhibitors of NADP-dependent isocitrate dehydrogenase and mitochondrial citrate expor

116 The crystal structure of Escherichia coli isocitrate dehydrogenase and sequence alignment of porci

117 stallographic structures of Escherichia coli isocitrate dehydrogenase and the distantly related Therm

118 ylic acid cycle (oxoglutarate dehydrogenase, isocitrate dehydrogenase) and glycine decarboxylase.

119 itrate to locate the metal-substrate site of isocitrate dehydrogenase, and 3) the use of reactive pep

120 e gene encoding the NADP(+)-dependent enzyme isocitrate dehydrogenase, and cadherin 18, type 2 (CDH14

121 ytosolic isoforms of NADP(+)/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of g

122 mes: malate dehydrogenase, citrate synthase, isocitrate dehydrogenase, and succinyl-CoA synthetase.

123 Deletion of the citC gene, coding for isocitrate dehydrogenase, arrests sporulation of Bacillu

124 hydrogenase alpha levels and lower levels of isocitrate dehydrogenase, both proteins involved in the

125 was consistent with allosteric inhibition of isocitrate dehydrogenase by P-enolpyruvate.

126 ase and to stimulate the reverse reaction of isocitrate dehydrogenase (carboxylation of alpha-KG to i

127 Isocitrate dehydrogenase catalyses the two step, acid ba

128 The downstream isocitrate dehydrogenase (citC) gene appears to be part

129 echanism of regulation by phosphorylation of isocitrate dehydrogenase, cocrystallization of isocitrat

130 alate dehydrogenase than does the tetragonal isocitrate dehydrogenase conformation.

131 ydrogenase was used to express the enzyme in isocitrate dehydrogenase-deficient E. coli.

132 insulin secretion is amplified by cytosolic isocitrate dehydrogenase-dependent transfer of reducing

133 is indicates that eubacterial NADP-dependent isocitrate dehydrogenases (EC 1.1.1.42) first evolved fr

134 hia coli, the homodimeric Krebs cycle enzyme isocitrate dehydrogenase (EcIDH) is regulated by reversi

135 Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur

136 e production of 2-hydroxyglutarate by mutant isocitrate dehydrogenase enzymes, we can observe metabol

137 Mechanistically, isocitrate dehydrogenase expression and the production o

138 Isocitrate dehydrogenase from Bacillus subtilis (BsIDH)

139 d on the crystal structure of NADP-dependent isocitrate dehydrogenases from Escherichia coli, Bacillu

140 we showed that citrate synthase, aconitase, isocitrate dehydrogenase, fumarase, malate dehydrogenase

141 Mutations in the isocitrate dehydrogenase gene (IDH1) were recently descr

142 with glioma harbor specific mutations in the isocitrate dehydrogenase gene IDH1 that associate with a

143 f the structure of the porcine NADP-specific isocitrate dehydrogenase generated by the Insight II Mod

144 Mutations in the isocitrate dehydrogenase genes (IDH1/2) occur often in d

145 glioma-associated mutations into the NADP(+ )isocitrate dehydrogenase genes (IDP1, IDP2, IDP3) in Sac

146 Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among t

147 occurring mutations in the NADP(+)-dependent isocitrate dehydrogenase genes IDH1 and IDH2 These mutat

148 e chromatin architecture at the promoters of isocitrate dehydrogenase genes to promote transcription

149 Two putative Methanococcus jannaschii isocitrate dehydrogenase genes, MJ1596 and MJ0720, were

150 ies of homologous isozymes of NADP+-specific isocitrate dehydrogenase, histidine-tagged forms of yeas

151 rs based on the DNA base sequence within the isocitrate dehydrogenase (icd) gene to amplify a 1,200-b

152 tigated the role of cytosolic NADP-dependent isocitrate dehydrogenase (ICDc) in control of GSIS in be

153 of isocitrate and engagement with cytosolic isocitrate dehydrogenase (ICDc) may be one key pathway,

154 ate carrier and the cytosolic NADP-dependent isocitrate dehydrogenase (ICDc), is involved in control

155 (via isocitrate lyase) or the TCA cycle (via isocitrate dehydrogenase (ICDH) activity) and we sought

156 her hand, between isocitrate lyase (ICL) and isocitrate dehydrogenase (ICDH) for their common substra

157 Isocitrate dehydrogenase (ICDH) is either an integral pa

158 e report here that cytosolic NADP+-dependent isocitrate dehydrogenase (ICDH) represents a new corneal

159 as determined to be in the icd gene encoding isocitrate dehydrogenase (ICDH).

160 harboring a mutation in the gene coding for isocitrate dehydrogenase ( IDH).

161 Mutant isocitrate dehydrogenase (IDH) 1 and 2 proteins alter th

162 1 and aminopeptidase), inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody-base

163 associated with disease progression such as isocitrate dehydrogenase (IDH) 1, IDH2, EZH2, serine/arg

164 Cit2 and reduced expression of NAD-specific isocitrate dehydrogenase (Idh) and aconitase (Aco1) in p

165 Triglyceride concentration and isocitrate dehydrogenase (IDH) and glucose-6-phosphate d

166 Mutations in isocitrate dehydrogenase (IDH) are the most prevalent ge

167 dinucleotide phosphate (NADP) by prokaryotic isocitrate dehydrogenase (IDH) arose around the time euk

168 Isocitrate dehydrogenase (IDH) catalyzes the oxidative d

169 porcine heart mitochondrial NADP+-dependent isocitrate dehydrogenase (IDH) complexed with Mn2+ and i

170 Aconitase and isocitrate dehydrogenase (IDH) enzyme activities were de

171 The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-

172 by the discovery of mutations involving the isocitrate dehydrogenase (IDH) enzymes.

173 ties between isocitrate and isopropylmalate, isocitrate dehydrogenase (IDH) exhibits a strong prefere

174 activity for grading and characterization of isocitrate dehydrogenase (IDH) gene mutation status of g

175 ne promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined.

176 Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequen

177 Somatic mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur

178 talline porcine mitochondrial NADP-dependent isocitrate dehydrogenase (IDH) has been determined in co

179 NAD+-specific isocitrate dehydrogenase (IDH) has been reported to bind

180 Yeast mitochondrial NAD+-specific isocitrate dehydrogenase (IDH) has previously been shown

181 discovery of mutations in the genes encoding isocitrate dehydrogenase (IDH) has uncovered a critical

182 terozygous mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) in subsets of cancers, in

183 The human NAD-dependent isocitrate dehydrogenase (IDH) is a heterotetrameric mit

184 Isocitrate dehydrogenase (IDH) is a reversible enzyme th

185 Human NAD-dependent isocitrate dehydrogenase (IDH) is allosterically activat

186 Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an allosterically regu

187 Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an allosterically regu

188 Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an octamer containing

189 osteric regulatory properties, NAD+-specific isocitrate dehydrogenase (IDH) is believed to control fl

190 Among a number of novel genes, isocitrate dehydrogenase (IDH) is recurrently mutated in

191 Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 an

192 stigation of metabolic pathways disturbed in isocitrate dehydrogenase (IDH) mutant tumors revealed th

193 s caused by recurrent mutations, such as the isocitrate dehydrogenase (IDH) mutations found in 15% of

194 Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the met

195 ation in a subset of glioblastomas harboring isocitrate dehydrogenase (IDH) mutations, but metabolic

196 associated with MYC signaling, but not with isocitrate dehydrogenase (IDH) mutations, suggesting a d

197 Isocitrate dehydrogenase (IDH) of Escherichia coli is re

198 The tricarboxylic acid cycle NAD+-specific isocitrate dehydrogenase (IDH) of Saccharomyces cerevisi

199 mine the effects of large-scale variation in isocitrate dehydrogenase (IDH) or glucose-6-phosphate de

200 that shows how robust behavior arises in the isocitrate dehydrogenase (IDH) regulatory system of Esch

201 Small structural perturbations in the enzyme isocitrate dehydrogenase (IDH) were made in order to eva

202 Isocitrate dehydrogenase (IDH)(1) of Escherichia coli is

203 NAD+-dependent isocitrate dehydrogenase (IDH), a key regulatory enzyme

204 drogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH), advancing and challengin

205 zed for use in the crystallographic study of isocitrate dehydrogenase (IDH), as well as for general u

206 IDP2, and/or the mitochondrial NAD+-specific isocitrate dehydrogenase (IDH), metabolite measurements

207 Sequences of the icd gene, encoding isocitrate dehydrogenase (IDH), were obtained for 33 str

208 The human NAD-dependent isocitrate dehydrogenase (IDH), with three types of subu

209 We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combini

210 o homologous subunits of yeast NAD+-specific isocitrate dehydrogenase (IDH).

211 ta-N-acetylglucosamine transferase (OGT) and isocitrate dehydrogenase (IDH).

212 ide adenine dinucleotide phosphate-dependent isocitrate dehydrogenase (IDH)1 and IDH2 frequently aris

213 Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at th

214 imaging-defined invasive phenotypes of both isocitrate dehydrogenase (IDH-1)-mutated and IDH-1 wild-

215 ncode different subunits of NAD(+)-dependent isocitrate dehydrogenase (IDH; EC 1.1.1.41) were identif

216 Isocitrate dehydrogenases (IDH) convert isocitrate to al

217 scribed metabolic oncogenic factors: mutated isocitrate dehydrogenases (IDH), succinate dehydrogenase

218 glutarate (catalyzed by reverse flux through isocitrate dehydrogenase, IDH).

219 Here, we report that the isocitrate dehydrogenase IDH1 is the most strongly upreg

220 .35 million compounds against mutant (R132H) isocitrate dehydrogenase IDH1 led to the identification

221 lic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently

222 Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recen

223 utarate (2HG), generated by mutated forms of isocitrate dehydrogenase (IDH1 and IDH2), reduces the ex

224 Mutations in the cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDH1) occur in several types o

225 Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate

226 Ps harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displaye

227 rboxylated by the NADPH-linked mitochondrial isocitrate dehydrogenase (IDH2) to form isocitrate, whic

228 or a non-allosteric bacterial NAD+-specific isocitrate dehydrogenase (IDHa).

229 Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high le

230 Mitochondrial NAD(+)-specific isocitrate dehydrogenases (IDHs) are key regulators of f

231 mRNAs by yeast mitochondrial NADP+-specific isocitrate dehydrogenase (IDP1) but not by the correspon

232 Rat liver cytosolic NADP+-specific isocitrate dehydrogenase (IDP2) was expressed in bacteri

233 drogenase (ZWF1) or cytosolic NADP+-specific isocitrate dehydrogenase (IDP2), suggesting dependence o

234 he gene encoding cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDP2).

235 ndicate that either cytosolic NADP+-specific isocitrate dehydrogenase (Idp2p) or the hexose monophosp

236 ic source of NADPH, cytosolic NADP+-specific isocitrate dehydrogenase (Idp2p).

237 The conformation of isocitrate dehydrogenase in the orthorhombic crystal for

238 d outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetical

239 and the expression and activity of TETs and isocitrate dehydrogenases in primary human chondrocytes.

240 e FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs

241 search terms were used: IDH, IDH1, IDH2, and isocitrate dehydrogenase, in conjunction with glioma or

242 tice forces are fairly weak, it appears that isocitrate dehydrogenase is a flexible molecule that can

243 he basic structural/functional unit of yeast isocitrate dehydrogenase is a heterodimer of IDH1 and ID

244 Mammalian NAD-dependent isocitrate dehydrogenase is an allosteric enzyme, activa

245 Yeast NAD(+)-specific isocitrate dehydrogenase is an allosterically regulated

246 Yeast NAD(+)-specific isocitrate dehydrogenase is an allosterically regulated

247 Yeast mitochondrial NAD(+)-specific isocitrate dehydrogenase is an octamer composed of four

248 ts that His(309) of pig heart NADP-dependent isocitrate dehydrogenase is equivalent to His(339) of th

249 Pig heart NAD-dependent isocitrate dehydrogenase is inactivated by adenosine 5'-

250 Isocitrate dehydrogenase is mutated at a key active site

251 The new, orthorhombic crystal form of isocitrate dehydrogenase is related to the previously re

252 22% of the ATP needed for biosynthesis; (ii) isocitrate dehydrogenase is reversible in vivo; (iii) ab

253 Pig heart mitochondrial NADP-dependent isocitrate dehydrogenase is the most extensively studied

254 r to those previously reported for cytosolic isocitrate dehydrogenase isolated from a variety of tiss

255 acid substrate, comprising one subfamily and isocitrate dehydrogenase, isopropylmalate dehydrogenase,

256 Idp1p) or peroxisomal (Idp3p) NADP+-specific isocitrate dehydrogenase isozymes.

257 ch codes for the regulatory catalytic enzyme isocitrate dehydrogenase kinase/phosphatase (IDH K/P), a

258 hosphorylation catalyzed by the bifunctional isocitrate dehydrogenase kinase/phosphatase (IDHKP), and

259 stallization of isocitrate dehydrogenase and isocitrate dehydrogenase kinase/phosphatase in the prese

260 rmational changes, to accommodate binding to isocitrate dehydrogenase kinase/phosphatase.

261 The isocitrate dehydrogenase mutant, strain 5051, was constr

262 ts: expression was elevated in aconitase and isocitrate dehydrogenase mutants, diminished in alpha-ke

263 The mass spectra also indicate the isocitrate dehydrogenase mutation status of the tumor vi

264 anine-DNA methyltransferase-methylation, and isocitrate dehydrogenase mutation status, the proportion

265 prognostic and therapeutic consequences: (a) isocitrate dehydrogenase mutation; (b) the combined loss

266 features or genetic alterations, except for isocitrate dehydrogenase mutations (IDH(mut)) that were

267 t developments and implications in regard to isocitrate dehydrogenase mutations in chondrosarcoma, a

268 at might be relevant in cancer cells bearing isocitrate dehydrogenase mutations.

269 Isocitrate-dehydrogenase mutations (OR = 2.52, p = 0.026

270 ding the Idh2p subunit of the NAD+-dependent isocitrate dehydrogenase (NAD-IDH).

271 B, encoding the beta-subunit of NAD-specific isocitrate dehydrogenase (NAD-IDH, or IDH3), which is be

272 We measured tissue levels of NADP-linked isocitrate dehydrogenase (NADP-ICDH), glucose-6-phosphat

273 wo different cDNAs that encode NADP-specific isocitrate dehydrogenase (NADP-IDH) isozymes of soybean

274 NADP-specific isocitrate dehydrogenase (NADP-IDH, or IDH2), an enzyme

275 mRNAs and enzyme activities of the cytosolic isocitrate dehydrogenase or glucose-6-phosphate dehydrog

276 -(13)C]oxaloacetate to generate (13)CO(2) at isocitrate dehydrogenase, or decarboxylation of [1-(13)C

277 he expansion during growth on acetate, where isocitrate dehydrogenase provides 90% of the NADPH neces

278 Pig heart NADP-dependent isocitrate dehydrogenase requires a divalent metal catio

279 Pig heart mitochondrial NADP-dependent isocitrate dehydrogenase requires a divalent metal ion f

280 ein, and in the phosphorylation cycle of the isocitrate dehydrogenase, respectively.

281 f the Escherichia coli icd gene, encoding an isocitrate dehydrogenase similar to the enzyme from B. s

282 Isocitrate dehydrogenase subunits Idh1p and Idh2p were a

283 ystallographic structure of Escherichia coli isocitrate dehydrogenase suggest that both yeast subunit

284 d sequence alignment of porcine with E. coli isocitrate dehydrogenase suggests that the porcine Arg(1

285 mily as HIcDH, including isopropylmalate and isocitrate dehydrogenases, suggests all of the family me

286 glutarate in cells results from mutations to isocitrate dehydrogenase that correlate with cancer.

287 Isocitrate dehydrogenase, the icd gene product, has been

288 s maintained largely by transhydrogenase and isocitrate dehydrogenase, the mechanisms responsible for

289 sis of the crystal structure of E. coli NADP-isocitrate dehydrogenase, the residues Asp(253), Asp(273

290 t with a deletion in the citC gene, encoding isocitrate dehydrogenase, the third enzyme of the tricar

291 t with a deletion of citC, the gene encoding isocitrate dehydrogenase, the third enzyme of the tricar

292 er of a DeltaIDP3 strain lacking peroxisomal isocitrate dehydrogenase to medium with docosahexaenoate

293 oenolpyruvate carboxylase and NADP-dependent isocitrate dehydrogenase transcripts in the transgenic f

294 hat specifically binds an epitope of mutated isocitrate dehydrogenase type 1 (IDH1R132H), which is fr

295 of Insight II, a structure for porcine NADP-isocitrate dehydrogenase was built based on the X-ray co

296 tion was unsuccessful, a new crystal form of isocitrate dehydrogenase was obtained which provides ins

297 alpha, beta, and gamma subunits of the human isocitrate dehydrogenase was used to express the enzyme

298 rg99, and gamma-Arg97 of human NAD-dependent isocitrate dehydrogenase were chosen as candidates for m

299 ial and cytosolic isozymes of NADP+-specific isocitrate dehydrogenase were expressed in yeast using p

300 rom alpha-ketoglutarate (alpha-KG) by mutant isocitrate dehydrogenase, whereas l-(S)-2-HG is generate